Patient Information	Specimen Information	Client Information
FLANNERY, STEVEN **DOB: 10/11/1983 AGE: 39** Gender: M Fasting: Y Phone: 210.799.0292 Patient ID: 114104940 Health ID: 8573031116802708	Specimen: DZ509349C Requisition: 0023780 Lab Ref #: 114104940 Collected: 10/17/2022 / 09:34 CDT Received: 10/18/2022 / 02:59 CDT Reported: 10/19/2022 / 19:08 CDT	Client #: 97515592 MAIL9925 MARKS, LIANNE WALK-IN LAB-PWN PO BOX 898 AMITE, LA 70422-0898

COMMENTS: FASTING:YES

Test Name	In Range	Out Of Range	Reference Range	Lab
VLDL CHOLESTEROL				
TRIGLYCERIDES	96		<150 mg/dL	IG
VLDL-CALCULATION				IG
CHOLESTEROL, VERY LOW DENSITY LIPOPROTEIN	19		<30 mg/dL (calc)	
LIPID PANEL, STANDARD				
CHOLESTEROL, TOTAL	164		<200 mg/dL	IG
HDL CHOLESTEROL	52		> OR = 40 mg/dL	IG
TRIGLYCERIDES	96		<150 mg/dL	IG
LDL-CHOLESTEROL	93		mg/dL (calc)	IG
Reference range: <100 Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)				
CHOL/HDLC RATIO	3.2		<5.0 (calc)	IG
NON HDL CHOLESTEROL	112		<130 mg/dL (calc)	IG
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.				
HS CRP	<0.3		mg/L	IG
Reference Range Optimal <1.0 Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87. For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk. 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk. Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation. >10.0 Persistent elevation, upon retesting, may be associated with infection and inflammation.				
COMPREHENSIVE METABOLIC PANEL				IG
GLUCOSE	89		65-99 mg/dL	
			Fasting reference interval	

Patient Information	Specimen Information	Client Information
FLANNERY, STEVEN **DOB: 10/11/1983 AGE: 39** Gender: M Fasting: Y Patient ID: 114104940 Health ID: 8573031116802708	Specimen: DZ509349C Collected: 10/17/2022 / 09:34 CDT Received: 10/18/2022 / 02:59 CDT Reported: 10/19/2022 / 19:08 CDT	Client #: 97515592 MARKS, LIANNE

Test Name	In Range	Out Of Range	Reference Range	Lab
UREA NITROGEN (BUN)	17		7-25 mg/dL	
CREATININE	1.08		0.60-1.26 mg/dL	
EGFR	90		> OR = 60 mL/min/1.73m2	
The eGFR is based on the CKD-EPI 2021 equation. To calculate the new eGFR from a previous Creatinine or Cystatin C result, go to https://www.kidney.org/professionals/kdoqi/gfr%5Fcalculator				
BUN/CREATININE RATIO	NOT APPLICABLE		6-22 (calc)	
SODIUM	140		135-146 mmol/L	
POTASSIUM	4.1		3.5-5.3 mmol/L	
CHLORIDE	103		98-110 mmol/L	
CARBON DIOXIDE	25		20-32 mmol/L	
CALCIUM	10.0		8.6-10.3 mg/dL	
PROTEIN, TOTAL		**8.2 H**	6.1-8.1 g/dL	
ALBUMIN		**5.2 H**	3.6-5.1 g/dL	
GLOBULIN	3.0		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.7		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.8		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	77		36-130 U/L	
AST	18		10-40 U/L	
ALT	20		9-46 U/L	
HEMOGLOBIN A1c	5.0		<5.7 % of total Hgb	IG
For the purpose of screening for the presence of diabetes: <5.7% Consistent with the absence of diabetes 5.7-6.4% Consistent with increased risk for diabetes (prediabetes) > or =6.5% Consistent with diabetes This assay result is consistent with a decreased risk of diabetes. Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes in children. According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).				
MAGNESIUM	2.2		1.5-2.5 mg/dL	IG
HEPATIC FUNCTION PANEL				IG
PROTEIN, TOTAL		**8.2 H**	6.1-8.1 g/dL	
ALBUMIN		**5.2 H**	3.6-5.1 g/dL	
GLOBULIN	3.0		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.7		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.8		0.2-1.2 mg/dL	
BILIRUBIN, DIRECT	0.1		< OR = 0.2 mg/dL	
BILIRUBIN, INDIRECT	0.7		0.2-1.2 mg/dL (calc)	
ALKALINE PHOSPHATASE	77		36-130 U/L	
AST	18		10-40 U/L	
ALT	20		9-46 U/L	
LD	134		100-220 U/L	IG
CREATINE KINASE, TOTAL	46		44-196 U/L	IG

Patient Information	Specimen Information	Client Information
FLANNERY, STEVEN **DOB: 10/11/1983 AGE: 39** Gender: M Fasting: Y Patient ID: 114104940 Health ID: 8573031116802708	Specimen: DZ509349C Collected: 10/17/2022 / 09:34 CDT Received: 10/18/2022 / 02:59 CDT Reported: 10/19/2022 / 19:08 CDT	Client #: 97515592 MARKS, LIANNE

Test Name	In Range	Out Of Range	Reference Range	Lab
GGT	13		3-90 U/L	IG
TSH	1.39		0.40-4.50 mIU/L	IG
PROTHROMBIN TIME-INR				IG
INR	1.0			
Reference Range	0.9-1.1			
Moderate-intensity Warfarin Therapy	2.0-3.0			
Higher-intensity Warfarin Therapy	3.0-4.0			
PT	10.5		9.0-11.5 sec	
For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ104 (This link is being provided for informational/ educational purposes only.)				
SED RATE BY MODIFIED				IG
WESTERGREN	2		< OR = 15 mm/h	
CBC (INCLUDES DIFF/PLT)				IG
WHITE BLOOD CELL COUNT	5.7		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT		**5.87 H**	4.20-5.80 Million/uL	
HEMOGLOBIN		**17.7 H**	13.2-17.1 g/dL	
HEMATOCRIT	49.7		38.5-50.0 %	
MCV	84.7		80.0-100.0 fL	
MCH	30.2		27.0-33.0 pg	
MCHC	35.6		32.0-36.0 g/dL	
RDW	12.7		11.0-15.0 %	
PLATELET COUNT	195		140-400 Thousand/uL	
MPV	10.1		7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	3574		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1550		850-3900 cells/uL	
ABSOLUTE MONOCYTES	433		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	120		15-500 cells/uL	
ABSOLUTE BASOPHILS	23		0-200 cells/uL	
NEUTROPHILS	62.7		%	
LYMPHOCYTES	27.2		%	
MONOCYTES	7.6		%	
EOSINOPHILS	2.1		%	
BASOPHILS	0.4		%	
URINALYSIS, COMPLETE				IG
COLOR	YELLOW		YELLOW	
APPEARANCE	CLEAR		CLEAR	
SPECIFIC GRAVITY	1.007		1.001-1.035	
PH	7.5		5.0-8.0	
GLUCOSE	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
KETONES	NEGATIVE		NEGATIVE	
OCCULT BLOOD	NEGATIVE		NEGATIVE	
PROTEIN	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
LEUKOCYTE ESTERASE	NEGATIVE		NEGATIVE	
WBC	NONE SEEN		< OR = 5 /HPF	
RBC	NONE SEEN		< OR = 2 /HPF	
SQUAMOUS EPITHELIAL CELLS	NONE SEEN		< OR = 5 /HPF	
BACTERIA	NONE SEEN		NONE SEEN /HPF	
HYALINE CAST	NONE SEEN		NONE SEEN /LPF	
This urine was analyzed for the presence of WBC, RBC, bacteria, casts, and other formed elements. Only those elements seen were reported.				

Patient Information	Specimen Information	Client Information
FLANNERY, STEVEN **DOB: 10/11/1983 AGE: 39** Gender: M Fasting: Y Patient ID: 114104940 Health ID: 8573031116802708	Specimen: DZ509349C Collected: 10/17/2022 / 09:34 CDT Received: 10/18/2022 / 02:59 CDT Reported: 10/19/2022 / 19:08 CDT	Client #: 97515592 MARKS, LIANNE

Test Name	In Range	Out Of Range	Reference Range	Lab
IRON AND TOTAL IRON BINDING CAPACITY				IG
IRON, TOTAL	97		50-180 mcg/dL	
IRON BINDING CAPACITY	300		250-425 mcg/dL (calc)	
% SATURATION	32		20-48 % (calc)	
FERRITIN	250		38-380 ng/mL	IG
VITAMIN B12	481		200-1100 pg/mL	IG
EBV EARLY ANTIGEN D AB (IGG)		**25.50 H**	U/mL	IG

U/mL	Interpretation
<9.00	Negative
9.00-10.99	Equivocal
>10.99	Positive

The potential exists for cross-reactivity with HIV (Human Immunodeficiency Virus) which could cause a false positive EBV-EA result.

ALPHA FETOPROTEIN, TUMOR MARKER	2.1		<6.1 ng/mL	IG

This test was performed using the Beckman Coulter chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. AFP levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease.

Patient Information	Specimen Information	Client Information
FLANNERY, STEVEN **DOB: 10/11/1983** **AGE: 39** Gender: M Fasting: Y Patient ID: 114104940 Health ID: 8573031116802708	Specimen: DZ509349C Collected: 10/17/2022 / 09:34 CDT Received: 10/18/2022 / 02:59 CDT Reported: 10/19/2022 / 19:08 CDT	Client #: 97515592 MARKS, LIANNE

Endocrinology

Test Name	Result	Reference Range	Lab
VITAMIN D,25-OH,TOTAL,IA	35	30-100 ng/mL	IG

```
Vitamin D Status          25-OH Vitamin D:

Deficiency:                     <20 ng/mL
Insufficiency:            20 - 29 ng/mL
Optimal:                  > or = 30 ng/mL
```

For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ199 (This link is being provided for informational/ educational purposes only.)

Physician Comments:

Immunology

Test Name	Result	Reference Range	Lab
ANA SCREEN, IFA, W/REFL TITER AND PATTERN			IG
ANA SCREEN, IFA	**POSITIVE**	NEGATIVE	

ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A positive ANA IFA result is suggestive of autoimmune disease and reflexes to titer and pattern. Further laboratory testing may be considered if clinically indicated.

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ177 (This link is being provided for informational/ educational purposes only.)

ANTINUCLEAR ANTIBODIES TITER AND PATTERN			IG
ANA TITER	**1:40 H**	titer	

A low level ANA titer may be present in pre-clinical autoimmune diseases and normal individuals.

```
Reference Range
<1:40         Negative
1:40-1:80     Low Antibody Level
>1:80         Elevated Antibody Level
```

ANA PATTERN	**Cytoplasmic**	

The presence of cytoplasmic fluorescence was noted on the HEp-2 slide. Other reactivities (e.g., anti- mitochondrial antibodies or anti-smooth muscle antibodies) may be responsible for this fluorescence. The clinical significance of this finding is uncertain. Clinical correlation is recommended.

AC-15 to AC-23: Cytoplasmic

International Consensus on ANA Patterns (https://doi.org/10.1515/cclm-2018-0052)

ANA TITER	**1:40 H**	titer

A low level ANA titer may be present in pre-clinical autoimmune diseases and normal individuals.

```
Reference Range
<1:40         Negative
1:40-1:80     Low Antibody Level
>1:80         Elevated Antibody Level
```

ANA PATTERN	**Nuclear, Speckled**	

Speckled pattern is associated with mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE), Sjogren's syndrome, dermatomyositis, and systemic sclerosis/polymyositis overlap.

AC-2,4,5,29: Speckled

Patient Information	Specimen Information	Client Information
FLANNERY, STEVEN **DOB: 10/11/1983** **AGE: 39** Gender: M Fasting: Y Patient ID: 114104940 Health ID: 8573031116802708	Specimen: DZ509349C Collected: 10/17/2022 / 09:34 CDT Received: 10/18/2022 / 02:59 CDT Reported: 10/19/2022 / 19:08 CDT	Client #: 97515592 MARKS, LIANNE

Immunology

Test Name	Result	Reference Range	Lab
International Consensus on ANA Patterns (https://doi.org/10.1515/cclm-2018-0052)			
Physician Comments:			

PERFORMING SITE:

IG QUEST DIAGNOSTICS-IRVING, 4770 REGENT BLVD., IRVING, TX 75063-2445 Laboratory Director: ROBERT L BRECKENRIDGE,MD, CLIA: 45D0697943